Cargando…

Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Detalles Bibliográficos
Autores principales:	Bai, Wei, Yang, Fan, Xu, Huji, Wei, Wei, Li, Hongbin, Zhang, Liyun, Zhao, Yi, Shi, Xiaofei, Zhang, Yan, Zeng, Xiaofeng, Leng, Xiaomei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388526/ https://www.ncbi.nlm.nih.gov/pubmed/37525264 http://dx.doi.org/10.1186/s13063-023-07546-z

Ejemplares similares

A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients
por: Bai, Wei, et al.
Publicado: (2023)

Baricitinib Liposomes as a New Approach for the Treatment of Sjögren’s Syndrome
por: Garrós, Núria, et al.
Publicado: (2022)

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

P1594: BARICITINIB FOR STEROID-RESISTANT/RELAPSE IMMUNE THROMBOCYTOPENIA (BAITP): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL
por: Zhao, Peng, et al.
Publicado: (2023)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Baricitinib/propofol: Pancreatitis following off-label use: case report
Publicado: (2022)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2023)

Baricitinib/lopinavir/ritonavir: Elevated transaminases and off-label use: case report
Publicado: (2020)

Baricitinib/ceftriaxone/metoclopramide: Extrapyramidal syndrome and off label use: case report
Publicado: (2021)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
por: Liu, Hui, et al.
Publicado: (2023)

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro
por: Dong, Jie, et al.
Publicado: (2022)

Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
por: Sun, Ziyi, et al.
Publicado: (2023)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Publicado: (2022)

Baricitinib/hydroxychloroquine: Various toxicities secondary to off-label use: 4 case reports
Publicado: (2021)

Childhood-onset primary Sjögren’s syndrome in a tertiary center in China: clinical features and outcome
por: Gong, Yinv, et al.
Publicado: (2023)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023)

Baricitinib/methylprednisolone/prednisolone: Elevated HBV DNA following an off label use: case report
Publicado: (2022)

Baricitinib/dexamethasone: Myalgia and elevated creatine kinase following an off-label use: case report
Publicado: (2022)

Consensus on targeted drug therapy for spondyloarthritis
por: Tian, Xinping, et al.
Publicado: (2023)

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
por: Hall, Frances C, et al.
Publicado: (2023)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

15. Eosinophilic pneumonitis secondary to baricitinib
por: Yein, Khin, et al.
Publicado: (2019)

Treatment of severe alopecia areata with baricitinib
por: Olamiju, Brianna, et al.
Publicado: (2019)

Baricitinib: Two Birds with One Stone
por: Saj, Fen, et al.
Publicado: (2022)

Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
por: Sun, Jing, et al.
Publicado: (2023)

High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
por: Li, Jun, et al.
Publicado: (2022)

Safety and efficacy of ciprofol vs. propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial
por: Liu, Yongjun, et al.
Publicado: (2022)

Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib
por: Posada, Maria M., et al.
Publicado: (2017)

Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII
por: Cheng, Cheng, et al.
Publicado: (2023)

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
por: Steinfeld, Serge D, et al.
Publicado: (2006)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Exploring the Target and Mechanism of Radix Paeoniae Alba on Sjogren’s Syndrome
por: Wu, Fangping, et al.
Publicado: (2023)

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
por: Deprez, Valentine, et al.
Publicado: (2020)

Baricitinib for COVID-19: a suitable treatment?
por: Favalli, Ennio G, et al.
Publicado: (2020)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Baricitinib: Various toxicities: 7 case reports
Publicado: (2021)

Baricitinib/cisatracurium besilate: Rhabdomyolysis: case report
Publicado: (2021)

Baricitinib: Various toxicities: 7 case reports
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bs4j7gvkb071ghmpf4gd8e5kec